In today’s rapidly evolving global landscape, launching therapies and medical devices demands more than traditional playbooks. Explore how AI & enabling technologies—from digital platforms to Direct-to-Disease models—are transforming launch strategies. 

This panel will also address global pricing dynamics, including MFN policies and U.S. regulatory impacts, as well as the need for innovation in the commercial model. 

• Tech is transforming global launches through digital platforms and Direct-to-Disease models.
• Global pricing dynamics like MFN and U.S. policy shifts are reshaping strategy.
• Commercial models must evolve to stay competitive in a changing landscape. 

Speakers 

Mike Ryan 

General Manager EVERSANA 

Alan Crowther 

General Manager EVERSANA 

Andrea Forgione 

Global Head, Access Policy, Patient Advocacy & Engagement - Primary and Specialty Care MENARINI Group 

Dan Lyons 

Senior Vice President, Head of International, Rare Tumors & Head of Global Access SpringWorks Therapeutics